One item that stands out clear here is the fact that there’s not enough money in grants from the government even with 451 million, as there’s another 50 million from Pharma and medical device companies subsidizing research as well. There has been so much talk about contributions of late, but where else would the needed money come from? BD
Even the big winners at the NIH trough can’t take the government’s research support for granted. Take the University of Pennsylvania, which pulled in $451 million in biomedical funding from NIH last year, second only to Johns Hopkins.
Nevertheless, Penn’s med school started an office five years ago to work with industry on research. And whatever you might think about the propriety of the approach, the dollars are rolling in. About $50 million in research support now comes from industry compared with about $20 million four or five years ago, Terry Fadem, head of Penn Medicine’s Office of Corporate Alliances, tells the Health Blog.
AstraZeneca, GlaxoSmithKline and Pfizer are among the companies that agree. They’ve signed multi-million dollar research contracts with Penn.
All told, more than 200 companies are now funding research at Penn. But doesn’t the company money come with strings attached? Fadem says Penn won’t agree to deals that restrict publication of results and that part of his office’s work includes monitoring consulting relationships between faculty and the private sector.
0 comments :
Post a Comment